Mayo Clinic investigators say a proof-of-concept study has demonstrated that induced pluripotent stem (iPS) cells can be used to treat heart disease. iPS cells are stem cells converted from adult stem cells so don't involve the ethical concerns involved in using human embryonic stem cells.
In their study, the researchers reprogrammed ordinary fibroblasts, cells that contribute to scars such as those resulting from a heart attack, converting them into stem cells that fix heart damage caused by infarction.
This is the first application of iPS-based technology for heart disease therapy. Previously iPS cells have been used on only three other disease models: Parkinson's disease, sickle cell anemia and hemophilia A. The ultimate goal is to use iPS cells derived from patients to repair injury. Using a person's own cells in the process eliminates the risk of rejection and the need for anti-rejection drugs. One day this regenerative medicine strategy may alleviate the demand for organ transplantation limited by donor shortage, the researchers say.
The findings appear in the current online issue of the journal Circulation.
"This study establishes the real potential for using iPS cells in cardiac treatment," says Timothy Nelson, M.D., Ph.D., first author on the Mayo Clinic study. "Bioengineered fibroblasts acquired the capacity to repair and regenerate infarcted hearts."
"This iPS innovation lays the groundwork for translational applications," comments Andre Terzic, M.D., Ph.D., Mayo Clinic physician-scientist and senior author. "Through advances in nuclear reprogramming, we should be able to reverse the fate of adult cells and customize 'on demand' cardiovascular regenerative medicine."From Damage to Repair
The Mayo Clinic team genetically reprogrammed fibroblasts via a "stemness-related" human gene set to dedifferentiate into an iPS cell capable of then redifferentiating into new heart muscle. When transplanted into damaged mouse hearts, iPS cells engrafted after two weeks, and after four weeks significantly contributed to improved structure and function of the damaged heart, in contrast to ineffective ordinary fibroblasts.
Compared to non-engineered fibroblasts, the iPS cells:
- Restored heart muscle performance lost after the heart attack
- Stopped progression of structural damage in the damaged heart
- Regenerated tissue at the site of heart damage
The Mayo research team included Almudena Martinez-Fernandez, Pharm.D.; Satsuki Yamada, M.D., Ph.D.; Carmen Perez-Terzic, M.D., Ph.D.; and Yasuhiro Ikeda, D.V.M., Ph.D.; along with Lois Rowe and Jonathan Nesbitt. The research was supported by the National Institutes of Health, American Heart Association, American Society for Clinical Pharmacology and Therapeutics, National Hemophilia Foundation, La Caixa Foundation Graduate Program, Marriott Individualized Medicine Program, Marriott Heart Disease Research Program, and Mayo Clinic.
